strong perform four new program pipelin tp
maintain buy rate maintain tp
provid upsid potenti
estim adjust ep
forward price-to-earnings multipl
estim base follow factor strong growth
total revenu acquisit nightstar
strong growth spinraza biosimilar segment
deliv solid perform global quarter
led four new program pipelin complet
acquisit nightstar provid two
potenti first class mid-to late-stag gene therapi
program specialti ophthalmolog initi two new
studi prioriti area multipl sclerosi
rais revenu guidanc
ep non- ep
expect growth revenu
growth revenu due advanc
pipelin acquisit
total revenu increas driven
part continu global launch spinraza
contribut revenu revenu growth also
driven biosimilar revenu increas
driven imraldi
gaap ep increas compar
non-gaap ep increas
compar
compani name inctickerbiibstock ratingbuyunchangedindustri viewoverweightpositivepric sep week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc| septemb
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
total us revenu spinraza increas
increas
increas primarili due
increas unit sale volum
biosimilar revenu increas
increas
increas due launch imraldi
partial off-set unfavor impact foreign
currenc exchang
multipl sclerosi ms revenu includ
royalti sale ocrevu increas versu
prior year global ms patient grew
low singl digit versu prior year prepar
expect launch vumer
repurchas share
compani common stock total valu
june cash cash equival
market secur total
note payabl gener net
cash flow oper
april publish data
open-label studi safeti toler spinraza
individu later-onset sma peer-review
journal neurolog medic journal
current price-to-earnings multipl
averag price-to-earnings stock price dip
quarter price-to-earnings trail
till septemb
expect forward price-to-earnings multipl
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend rate n/a forward annual dividend yield error trail annual dividend rate error trail annual dividend yield error year averag dividend yield error pay-out dividend date error ex-dividend date error last split factor new per last split date jan inform biogen inc| septemb
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
balanc sheet item short term invest total st account receiv total receiv inventori prepaid expens current asset total current asset gross properti plant accumul depreci net properti plant equip long-term invest tangibl defer tax asset long-term asset total asset equiti liabil account payabl accru expens current portion lt debt current incom tax payabl current liabil total current liabil long-term capit leas def tax liabil non-curr liabil total liabil common stock retain earn treasuri stock comprehens incom total common minor interest total equiti total liabil equiti actual annual actual quarterli inc| septemb
net cash flow provid oper activ increas compar
due higher net incom up-front payment made ioni upon
close ioni agreement charg reflect premium paid
purchas ioni common stock prior year compar period partial off-set chang
net cash flow provid invest activ declin compar
cash flow due decreas net proce relat market
secur cash use acquisit nst partial off-set decreas conting payment
made former sharehold fumapharm ag holder right payment
made ioni reflect fair valu common stock purchas upon close ioni
agreement proce receiv sale strateg invest
net cash use financ activ decreas compar
due net distribut non control interest reflect payment made neurimmun
subon ag exchang reduct royalti rate payabl off-set increas cash
use share repurchas
incom depreci amort goodwil intang depreci amort total loss sale asset loss sale invest stock-bas compens oper activ chang account receiv chang inventori chang net oper asset oper invest activ capit expenditur acquisit invest market equiti secur invest activit invest financ activ long-term debt issu total debt issu long-term debt repaid total debt repaid issuanc common stock repurchas common stock common prefer stock dividend paid- financ chang equival foreign exchang rate adjust net chang actual annual actual quarterli inc| septemb
deliv solid perform global second quarter led four
new program pipelin
compar
total revenu increas compar
total product revenu increas
compar total revenu
therapeut program increas
compar
revenu increas compar
revenu collabor relationship
increas compar
royalti corpor revenu increas compar
sale exclud amort impair acquir intang
asset increas compar
product cost sale increas
compar royalti cost sale
decreas compar
royalti cost sale
decreas
compar
 expens decreas compar
decreas due decreas cost incur
connect compani late stage program mileston up-front
expens decreas compar
earli stage program increas compar
late stage program decreas compar
decreas due discontinu
global phase trial aducanumab net eisai reimburs lower spend
relat develop diroximel fumar ms pursuant
licens collabor agreement alkerm pharma ireland limit
subsidiari plc lower spend relat develop
elenbecestat ad pursuant collabor arrang
eisai
research discoveri
mileston up-front expens
decreas late stage program partial off-set increas
spend relat develop earli ad pursuant
compani collabor arrang eisai advanc
late stage program glibenclamid larg hemispher
infarct lhi advanc late stage program
tofersen al advanc late stage program
sg expens increas compar
increas partial off-set decreas
oper spend associ pre-commerci cost relat
ad program follow discontinu global phase trial
aducanumab march
amort impair acquir intang asset decreas
compar gain
fair valu remeasur conting consider
compar loss
net profit-shar expens compar
incom oper increas
compar
compar
incom oper
increas
compar
decreas
compar
net expens increas compar
increas due net loss total
recogn invest relat hold equiti debt secur
compar net gain total
net loss recogn reflect decreas fair valu
invest ioni common stock march loss recogn
sale portion invest ioni common stock
reflect decreas fair valu share sold march
proce sale portion share ioni common stock
total origin cost basi share upon acquisit
incom tax expens decreas compar
decreas due combin
intern reorgan certain intellectu properti right relat
inter-company sale intellectu properti higher effect tax rate
result sale inventori tax effect
includ prepaid tax januari higher effect tax rate
net incom increas
compar
net equiti loss investe net incom increas
compar non-
net incom increas compar
gaap ep increas compar
non-gaap ep increas compar
total revenu increas compar
total product revenu increas
compar
total revenu therapeut program increas
compar
total revenu increas compar
revenu collabor relationship
increas compar
royalti corpor revenu increas
compar reserv discount
allow gross product revenu
compar
sale exclud amort impair acquir intang
asset increas compar
product cost sale increas
compar increas due higher contract
manufactur shipment increas sale biosimilar product
increas inventori amount written result excess
obsolesc unmarket reason increas
partial off-set lower product cost sale associ ms
increas product cost sale also due sale bioverativ
remain hemophilia-rel inventori hand cost basi
total pursuant term manufactur
suppli agreement bioverativ enter connect spin-off
hemophilia busi
product cost sale
increas
compar
royalti cost sale
decreas
compar
royalti cost sale decreas compar
decreas due decreas royalti payabl
sale tysabri result expir certain third parti royalti
partial off-set increas royalti payabl higher sale
spinraza imraldi
 expens decreas compar
decreas due decreas mileston
decreas partial off-set increas cost incur
connect earli stage program decreas mileston
up-front expens primarili relat close ioni
mileston up-front expens decreas
compar decreas primarili due
recognit net charg research develop
expens upon close ioni agreement new
exclus agreement ioni develop novel antisens oligonucleotid drug
candid broad rang neurolog diseas
expens also reflect recognit charg research
develop expens upon enter compani collabor
research develop servic agreement skyhawk
late stage program increas compar
earli stage program increas
compar
increas earli stage program primarili due
gosuranemab psp pursuant licens agreement bristol-my squibb
compani parkinson diseas ampa cognit
impair associ schizophrenia cia
mileston up-front
expens decreas
compar
increas
compar
increas partial off-set decreas cost associ
develop vixotrigin trigemin neuralgia tgn
advanc lhi late stage program
advanc tofersen al late stage program
decis octob discontinu develop vixotrigin
treatment pain lumbosacr radiculopathi decis decemb
discontinu develop investig aav-bas
gene therapi treatment x-link retinoschisi
investig aav-bas gene therapi treatment xlrp upon
termin collabor agreement appli genet
sg expens increas compar
increas due acquisit relat charg
incur connect recent acquisit nst total
includ stock-bas compens expens associ
acceler vest stock option previous grant nst
employe post-combin servic perform increas legal
patent fee increas commerci cost primarili relat
spinraza compani continu expand new intern
amort impair acquir intang asset decreas
compar
decreas primarili due net overal decreas compani
expect rate amort acquir intang asset due
lower amort subsequ impair us licens
forward pharma a/ intellectu properti includ forward pharma
intellectu properti relat tecfidera higher expect lifetim
revenu tysabrri impair charg
compar
compar
record loss condens consolid statement
incom estim loss includ pre-tax loss
reflect decreas compani origin estim
march reflect current estim fair valu asset liabil
held sale adjust expect cost sell hillerod denmark
manufactur oper compani estim fair
valu advers commit approxim associ
guarante futur minimum batch product hillerod facil
record tax expens relat propos
transact gain fair valu remeasur conting consider
increas compar
increas primarili due chang probabl expect time
achiev certain develop mileston partial off-set decreas
interest rate use revalu conting consider liabil
passag time
net profit-shar expens compar
increas due increas collabor profit
result increas biosimilar sale
incom oper increas
compar net incom
compar expens chang
reflect net gain total recogn invest relat
hold equiti debt secur compar net loss total
net gain recogn reflect increas fair valu invest
ioni common stock decemb partial off-set loss
recogn sale portion invest ioni common stock
reflect decreas fair valu share sold march
fair valu
remeasur
increas
compar
incom oper
increas
compar
incom tax expens increas compar
effect tax rate decreas
compar decreas due
combin intern reorgan certain intellectu properti
right off-set tax expens relat propos divestitur
subsidiari own hillerod denmark manufactur oper
higher effect tax rate result sale inventori tax
effect includ within prepaid tax januari
net equiti loss investe loss reflect biogen
share loss total amort basi differ total
net incom increas compar
gaap ep increas compar
non-gaap ep increas compar
total product revenu increas compar
increas
compar
total product revenu increas
compar decreas
compar
total product revenu rest world increas
compar increas
compar
gaap ep increas
compar
increas
compar
tecfidera revenu increas
compar total us revenu increas
compar
increas us revenu primarili due price increas
lower decreas channel inventori level compar
partial off-set higher rate discount allow
total revenu increas compar
total us revenu increas
compar increas
due price increas partial off-set decreas unit sale
volum higher rate discount allow
total revenu rest world increas
compar increas
compar
increas rest world revenu primarili due
increas unit sale volum period primarili relat
biogen european japanes market partial off-set price
reduct certain european countri
anticip increas tecfidera demand global basi
compar notwithstand increas competit
addit treatment ms
compani also expect volum growth intern market
exceed volum declin us price reduct certain
increas
compar
total revenu
rest world increas
increas
decreas
decreas
interferon revenu decreas
compar decreas
compar
total us revenu decreas
compar decreas
compar
decreas
decreas
decreas revenu due decreas interferon unit
sale volum primarili
attribut patient transit ms therapi higher rate
discount allow partial off-set price increas
total revenu rest world decreas
compar decreas
compar
decreas rest world revenu primarili due
price reduct certain european countri partial off-set
increas interferon unit sale volum
compani expect interferon revenu continu declin
us market compar
result increas competit ms product well
treatment ms includ biosimilar price reduct
certain european market
tysabri revenu increas
compar increas
compar
total us revenu decreas
compar decreas
compar
decreas revenu primarili due decreas unit
sale volum partial off-set price
total revenu rest world increas
compar increas
compar
increas primarili due increas unit sale volum
compani anticip tysabri demand stabl global basi
compar expect volum declin us due
increas competit addit treatment ms includ
ocrevu off-set volum growth intern market
spinraza revenu increas
compar increas
compar
total us revenu increas compar
increas
compar increas
primarili due increas unit sale volum
decreas
decreas
increas
increas
total revenu rest world increas
compar
increas unfavor impact due time
shipment occur advanc expect commerci
total revenu rest world increas
compar increas due
reach price reimburs agreement franc
result recognit addit revenu relat
sale period august date upon compani
began sell spinraza franc decemb compani
chang estim amount revenu signific
revers probabl
decreas rest world also due increas unit sale
volum partial off-set
unfavor impact foreign currenc exchang
compani expect rate spinraza revenu grow
moder compar primarili due lower rate
new patient start combin impact load dose dynam
patient transit dose everi four month
face competit new gene therapi product
approv us may treatment sma addit
compani awar product develop
success develop approv may compet spinraza
sma market futur sale spinraza may affect
commerci compet product
increas
compar
new gene therapi
product
approv us
may
treatment sma
benepali flixabi imraldi
biosimilar revenu increas
compar increas
compar
increas primarili due launch imraldi
partial off-set unfavor impact foreign currenc exchang
expect strong
revenu growth biosimilar busi primarili driven
continu launch imraldi
benepali revenu increas
compar increas
compar
flixabi revenu increas compar
increas compar
imraldi revenu
revenu program
share pre-tax profit rituxan gazyva
compar
compar
total product revenu increas
compar increas
compar
increas
increas
increas
increas
revenu program
increas product revenu us primarili due
increas net sale rituxan us
increas net sale rituxan us reflect
sell price increas partial off-set higher discount
increas product revenu also reflect increas gazyva
unit sale volum increas
net sale rituxan us reflect increas unit sale volum
decreas collabor cost expens primarili due
lower sell market cost rituxan lower brand
pharmaceut drug free expens rituxan gazyva
awar molecul includ biosimilar product
develop success develop approv may compet
rituxan fda approv rituximab biosimilar
biosimilar rituxan could come market us
may advers affect pre-tax profit compani
collabor arrang genentech would turn
advers affect co-promot profit us futur year
increas product
revenu us
primarili due increas
net sale rituxan
us
nobil phase
studi investig
safeti efficaci
gazyva adult
june juli present new result nurtur
studi ad data longest studi spinal muscular atrophi sma
pre-symptomat infant data report month
analysi continu demonstr efficaci safeti patient treat
pre-symptomat spinraza comparison natur histori
new data also show patient treat spinraza
continu improv overwhelm major patient
achiev motor mileston normal time-frame data
present cure sma annual sma confer anaheim calif june
congress european academi neurolog
oslo norway june
june roch announc top-line result nobil phase studi
investig safeti efficaci gazyva adult prolif
lupu nephriti studi met primari endpoint show gazyva
combin standard care demonstr enhanc efficaci
compar placebo plu standard care alon achiev complet renal
respons one year
renal respons serolog marker diseas activ compar
placebo us gazyva part collabor
genentech inc wholly-own member roch group
june present new data european congress
rheumatolog eular madrid spain june data
includ real-world evid compani biosimilar anti-tnf
portfolio includ benepali etanercept flixabi infliximab
imraldi adalimumab confirm safeti efficaci
biosimilar high adher patient treatment
june eular confer collabor partner ucb
present interim result phase studi dapirolizumab pegol
dzp patient activ system lupu erythematosu sle despit
complet acquisit
nst clinical-stag
focus adeno-
treatment inherit
primari endpoint studi demonstr dose respons
week british isl lupu assess group bilag base composit
lupu assess bicla studi demonstr consist
potenti meaning improv major clinic endpoint
patient treat dzp compar placebo addit biomark data
demonstr evid proof biolog dzp well toler
demonstr accept safeti profil
june complet acquisit nst clinical-stag gene
therapi compani focus adeno-associ viru treatment inherit
retin disord result acquisit ad two mid-to late-
stage clinic asset well preclin program ophthalmolog
total transact valu take account transact
expens cash acquir close
may present new interim data on-going open-label
pivot studi relaps ms rm annual
meet consortium multipl sclerosi center seattl
data indic diroximel fumar gener well toler
significantli reduc diseas activ newli diagnos rm patient
previous treat interferon glatiram acet treatment
discontinu due gastrointestin event occur low rate one
year diroximel fumar novel oral fumar candid develop
pharma ireland limit subsidiari plc
may collabor partner eisai co ltd dose first
patient global phase studi clariti ad earli
may nation institut excel
unit kingdom recommend fund spinraza nation
health servic posit recommend treatment infant
children adult sma includ pre-symptomat sma type
may present new data ms portfolio
annual meet american academi neurolog philadelphia
pa may present includ data safeti
efficaci diroximel fumar studi updat safeti
analys evalu extend interv dose approxim everi six
week natalizumab compar approv everi four-week dose
data demonstr treatment tecfidera significantli slow
rate whole brain volum loss compar placebo
may present new data annual meet
affirm safeti durabl spinraza includ data
shine extens studi patient follow four year
nurtur studi pre-symptomat infant
may annual meet european
network cure al meet tour franc may
present interim result phase studi tofersen
antisens oligonucleotid studi potenti treatment
amyotroph later sclerosi al adult confirm superoxid
data demonstr statist signific reduct protein
level numer trend toward slow clinic declin
patient treat tofersen compar placebo
april publish data open-label studi
safeti toler spinraza individu later-onset sma
peer-review journal neurolog medic journal
data show individu later-onset sma treat
spinraza regain motor function previous lost
treatment stabil diseas activ lead improv
activ daili live
publish data
open-label
studi safeti
toler spinraza
individu later-
onset sma peer-
neurolog medic
journal
rang
non-gaap
ep rang
perform global
second quarter led
four new program
expect revenu rang
expect ep rang non-
ep rang
tax rate expect rang
non-gaap sg expens expect total
revenu
deliv solid perform global second quarter led
four new program pipelin total revenu increas
compar increas
compar
gaap ep increas compar
non-gaap ep increas compar
ep increas compar
non-gaap ep increas
compar
total product revenu increas
compar decreas
compar
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
gross margin ttm basi compar
net margin improv ttm basi compar
ep growth ttm basi compar
revenu growth ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc| septemb
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale biogen inc| septemb
invest flow
mrqyoy growth revenu growthoper incom growthep mrqcapex salescap ex salesfre mrq ratio growth yoy oper growth yoy free growth mrqfinanci mrqreturn mrqreturn asset biogen inc| septemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset day sale day account day convers inventori cog inventori tax rate net incom net net margin annual itemsquarterli item biogen inc| septemb
outstand equival market debt purchas properti plant purchas purchas sale repurchas net issuanc net chang capit free inc| septemb
current price-to-earnings multipl averag price-to-earnings stock price dip
quarter price-to-earnings trail till septemb
expect forward price-to-earnings multipl
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvalueblackrock vanguard group inc primecap manag clearbridg invest capit world investor wellington manag compani aqr capit manag geod capit manag top mutual fund holdersholdersharesd report outvaluevanguard/primecap vanguard total stock market vanguard vanguard specialized-health legg mason clearbridg aggress growth spdr etf vanguard horizon fund-capit opportun growth fund america vanguard institut fund-institut etf tr- qqq tr seri inc| septemb
developmentsdiroximel fumar demonstr significantli improv gastrointestin toler profil compar dimethyl fumar patient multipl sclerosisjuli plc inc today announc posit top-line result larg random double-blind five-week phase studi diroximel fumar investig novel oral fumar distinct chemic structur relapsing-remit multipl sclerosi compar tecfidera diroximel fumar statist superior dimethyl fumar studi pre-specifi primari endpoint patient treat diroximel fumar self-report significantli fewer day key gastrointestin symptom intens score individu gastrointestin symptom impact scale compar dimethyl fumar complet acquisit nightstar june today announc complet acquisit nightstar clinical-stag gene therapi compani focus adeno-associ viru aav treatment inherit retin disord result acquisit ad two mid-to late-stag clinic asset well preclin program opthamolog total transact valu take account expect transact expens cash close nst common stock longer list trade nasdaq global select market recommend stockhold reject below-market mini-tend offer capit corporationmay today announc receiv notic unsolicit mini-tend offer capit corpor capit purchas share common stock price per share cash endors capit unsolicit mini-tend offer recommend stockhold tender theri share respons capit offer offer price current market price share subject numer condit affili associ way capit mini-tend offer offer document inc| septemb
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
ytd stock perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc| septemb
consensu view analyst trend stock
low
compar
average
forward price-to-earnings
average
biib avgfive-year growth forecast usdgrowth high day day day estim comparisonbiibindustri avg avgprice/earn yield inc| septemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr biogen inc| septemb
incom statement
guidanc
non-gapp
per share item
product perform develop
valuat consensu perform
stock price volatil quarter gave return current trade
averag volum share trade
stock price volatil till march show huge dip drug failur march
stock price declin past rang stock
stock price show huge fluctuat past stock declin past
stock surg septemb declin may
crispidea price target maintain due continu global launch spinraza
strong growth imraldi recommend buy rate stock base strong oper
perform quarter new program ad pipelin
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
